Trailing-twelve-month (TTM) revenue is $1.47 Billion with a year-over-year growth of +12.39%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $357,800,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $360,855,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-25 |
| Q1 FY2026Period ended 2026-03-31 | $362,258,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $390,600,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $1,471,513,000 |
Current P/S: $4,132,996,145 market capitalization ÷ $1,471,513,000 TTM revenue = 2.81x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T15:15:16.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $390.60M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:17:35.811Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Advanced Circulatory Support Segment | N/A | $55M | $39M | $40M | N/A | N/A |
| Cardiopulmonary Segment | N/A | $483M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Europe | $193M | $202M | $179M | $215M | $220M | $269M |
| Locations Excluding The United States And Europe | $272M | $263M | $271M |
$1.47B
$1.47 Billion
+12.39%
vs. $1.31B a year ago (TTM)
+7.57%
5 Year compound annual growth rate
1 Year
+12.39%
3 Year
+10.70%
5 Year
+7.57%
10 Year
+15.60%
15 Year
+14.43%
20 Year
+13.08%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $1.39B | +$134.66M | +10.74% |
| 2024 | $1.25B | +$99.89M | +8.66% |
| 2023 | $1.15B | +$131.74M | +12.89% |
| 2022 | $1.02B | ($13.56M) | (1.31%) |
| 2021 | $1.04B | +$101.12M | +10.82% |
| 2020 |
TTM Growth
+12.39%
3-Year CAGR
+10.70%
5-Year CAGR
+7.57%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T15:17:35.811Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $500M |
| $589M |
| $684M |
| $785M |
| Cardiovascular Segment | $577M | N/A | N/A | N/A | N/A | N/A |
|---|
| Neuromodulation Segment | $354M | $456M | $477M | $520M | $554M | $593M |
|---|
| $338M |
| $379M |
| UNITED STATES | $469M | $571M | $572M | $635M | $695M | $740M |
|---|
| $934.24M |
| ($149.93M) |
| (13.83%) |
| 2019 | $1.08B | ($22.83M) | (2.06%) |
| 2018 | $1.11B | +$94.70M | +9.35% |
| 2017 | $1.01B | ($201.60M) | (16.61%) |
| 2016 | $1.21B | +$922.34M | +316.35% |
